Cannabis Rescheduling Explained: Legal, Regulatory, and Policy Impacts

Recorded February 5, 2026 | 3:00PM–4:30PM ET | On-Demand Webinar

Overview

This webinar will provide a practical overview of the request to expedite federal cannabis rescheduling and the impact of President Trump’s Executive Order. Our panel of experts will explain what moving cannabis from Schedule I to Schedule III would mean for medical research, patients, and industry, as well as the potential interaction between federal rescheduling and state cannabis regulatory frameworks. Panelists will also discuss how the order addresses CBD and hemp, including calls for expanded access to full-spectrum, hemp-derived CBD, and congressional efforts to clarify hemp definitions and product safety standards. Attendees will come away with knowledge of key issues to watch if and when implementation moves forward.

$149

Members

$249

Non-Members

Speakers

Jonathan Havens
Read Bio
Partner and Co-Chair, Cannabis Law, Saul Ewing Arnstein & Lehr LLP, and Member, FDLI Board of Directors

Shane Pennington
Read Bio
Partner, Blank Rome LLP

Gillian Schauer
Read Bio
Executive Director, Cannabis Regulators Association (CANNRA)

Moderated by Patricia J. Zettler
Read Bio
John W. Bricker Professor of Law, The Ohio State University

FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals also may be honored by other states. The CLE credits will be posted as they are granted and registrants can request to be notified when approval is received.